Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

The Safety of Autologous Lyophilized Plasma Versus Fresh Frozen Plasma in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00968487
Recruitment Status : Completed
First Posted : August 31, 2009
Last Update Posted : February 24, 2012
Information provided by (Responsible Party):
HemCon Medical Technologies, Inc

Tracking Information
First Submitted Date  ICMJE August 26, 2009
First Posted Date  ICMJE August 31, 2009
Last Update Posted Date February 24, 2012
Study Start Date  ICMJE June 2010
Actual Primary Completion Date December 2011   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 28, 2009)
To assess the safety and tolerability of increasing doses of infused autologous units of LyP in normal healthy volunteers and to define possible LyP adverse reactions. [ Time Frame: 1 day, 7 day, 14 day, and 28 day follow-ups after infusion. ]
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT00968487 on Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: August 28, 2009)
To demonstrate that coagulation function assays and specific coagulation factors [Cohort 3 only] are similar within clinically meaningful levels, post-infusion of either autologous LyP or FFP. [ Time Frame: 1 day, 7 day, 14 day, and 28 day follow up after second infusion. ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE The Safety of Autologous Lyophilized Plasma Versus Fresh Frozen Plasma in Healthy Volunteers
Official Title  ICMJE A Clinical Study of the Safety of Ascending Doses of Autologous Lyophilized Plasma Versus Fresh Frozen Plasma in Normal Healthy Volunteers
Brief Summary A single-site, single-blind study of ascending doses of Lyophilized Plasma in normal healthy volunteers.
Detailed Description This "first-in-human" Phase I, single-center, dose escalation study (using 3 dose levels) is proposed to assess the safety of infusing reconstituted lyophilized human plasma (LyP). The study design incorporates plasmapheresis-derived autologous plasma (FFP) for infusion(s) to eliminate variables and events known to be related to allogenic transfusion. Subjects will be enrolled at a blood center and provide autologous FFP that will be shipped to the sponsor site and used as the starting material to manufacture LyP. Once manufacturing is complete, the LyP (autologous) will be returned to the blood center for reconstitution and infusion into subjects. Maximum dosage within this study will approach "massive transfusion" (1 liter in Cohort 3) to obtain a preliminary assessment of safety. One half of the FFP obtained from subjects in Cohort 3 (only) will be shipped to the sponsor and returned to the site (but not manufactured into LyP) to serve as the control (autologous FFP).
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Condition  ICMJE Healthy
Intervention  ICMJE
  • Biological: Lyophilized Plasma
    Lyophilized Plasma is serves as a source of plasma proteins for subjects who are deficient in plasma proteins. The donor and recipient are the same person, therefore the process is autologous. HemCon's lyophilized plasma originates from FFP from screened individual donors to significantly reduce the risk of bloodborne disease transmission and undesired transfusion-associated reactions. Each single-donor unit is tested (per required of the blood supply) to reduce the risk of transmission of infectious agents and hence, maximize subject safety.
  • Other: Fresh Frozen Plasma
    The fluid portion of one unit of human blood that has been centrifuged, separated, and frozen solid at −18 °C (−0.4 °F) (or colder) within 6 hours of collection.
Study Arms  ICMJE
  • Experimental: Lyophilized Plasma
    Intervention: Biological: Lyophilized Plasma
  • Active Comparator: Fresh Frozen Plasma
    Intervention: Other: Fresh Frozen Plasma
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: August 28, 2009)
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE December 2011
Actual Primary Completion Date December 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Males and non-pregnant/ non-breast feeding females as they present interest
  • Minimum weight, 140 pounds (64 kg) or 175 pounds for Cohort 3 only
  • Ages 18-55 years
  • Subject self-reports that he/she feels well and healthy
  • Subject is able to donate one unit of whole blood based on the AABB donor history questionnaire with modifications indicated. Volunteers with history of travel which puts them at risk for vCJD will be eligible to participate.
  • Has read the educational materials on donating blood and has had his/her questions answered
  • Able and willing to provide informed consent
  • Available for the duration of the trial (approximately 8 weeks for Cohorts 1 and 2 and 12 weeks for Cohort 3) and able to come to the treatment clinic for scheduled study visits.
  • Females of childbearing potential should either be surgically sterile (hysterectomy or tubal ligation), or should use a highly effective medically accepted contraceptive regimen. A highly effective method of birth control is defined as those which result in a lower failure rate (i.e., less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or vasectomized partner.
  • Female subjects must have a negative serum pregnancy test prior to enrollment.
  • Understands the English language
  • Scored greater or equal to 35 on the Duke Activity Status Index (DSAI)

Exclusion Criteria:

  • Known liver, kidney, cardiovascular, neurologic, gastrointestinal, blood, endocrine/ metabolic, autoimmune or pulmonary disease; treated or untreated hypertension (see precise cut-off below)
  • Cancer of any kind, under treatment or resolved
  • Known or past coagulopathy conditions or blood disease
  • Currently using medications for anticoagulant therapy
  • Currently taking fish oil supplements
  • Any conditions, medications, etc. on the AABB medical deferral list
  • Previous use of clotting factor concentrate(s)
  • Past diagnosis of stroke or transient ischemic attack
  • Current or history of drug or alcohol abuse. Used needles to take drugs, steroids, or anything not prescribed by a doctor
  • Known human immunodeficiency virus- or acquired immunodeficiency syndrome-related illness or received a positive test result for HIV infection.
  • Current or past infection with Hepatitis B or Hepatitis C virus
  • Has received positive test for Syphilis
  • Has received positive test for West Nile Virus
  • Female subject who is pregnant, lactating or with a positive pregnancy test
  • Currently taking an antibiotic or another medication for an infection.
  • Treatment or use of aspirin (or other platelet inhibiting agents) within 14 days of study donation and infusion visits
  • In the past week, has had a headache and fever at the same time.
  • Known intolerance to citric acid.
  • Receipt of blood or blood products within the past 12 months
  • Systolic blood pressure greater than 180 mmHg
  • Diastolic blood pressure greater than 90 mmHg
  • Temperature greater than 100° F
  • Hematocrit will not be less than 38% for both male and female donors
  • History of current mental or psychiatric condition
  • Treatment with any investigational agent within one month before treatment application for this trial
  • Unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental or social) that is likely to affect the subject's return for follow-up visits on schedule
  • Other unspecified reasons that, in the opinion of the Investigator, make the subject unsuitable for enrollment
  • Subject is institutionalized because of legal or regulatory order
  • Other criteria based upon the AABB universal donor history questionnaire with the exception of travel to a vCJD area (i.e. travel to a vCJD area is not a study exclusion).
  • Has had any vaccinations or injections in the past 8 weeks.
  • Is a Medicare recipient
  • Is uninsured (does not have health care insurance)
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 55 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT00968487
Other Study ID Numbers  ICMJE 2009-I-LyP-1
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party HemCon Medical Technologies, Inc
Study Sponsor  ICMJE HemCon Medical Technologies, Inc
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Jose Cancelas, M.D., Ph.D. Hoxworth Blood Center
PRS Account HemCon Medical Technologies, Inc
Verification Date February 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP